European Union
Hemispherx Biopharma Receives Orphan Drug Designation for Ampligen(R) to Treat Ebola Virus Disease
Hemispherx Biopharma, Inc. has announced that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen(R), an experimental therapeutic, to treat Ebola Virus Disease (EVD). This designation is a crucial step toward commercial approval,